The global creatinine measurement market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%. The increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rising geriatric population, and increasing number of drug development initiatives are the key drivers for global creatinine measurement market.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206847385
North America to dominate the creatinine measurement market
In 2018, North America is expected to dominate the market followed by Europe. The large share of North America is attributed to factors such as the increasing incidence of renal disorders, rising prevalence of other chronic disorders like hypertension and diabetes (which can lead to renal dysfunction) in the region, and the implementation of favorable government initiatives to increase awareness about kidney diseases and their early diagnosis.
The creatinine measurement market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include F. Hoffmann-la Roche Ltd (Switzerland)., Abbott Laboratories (US), Danaher Corporation (US), Thermo Fisher Scientific Inc (US), Siemens Healthineers (Germany), Randox Laboratories (UK)., Pointe Scientific, Inc (US), Sentinel Ch. Spa. (Italy), Diasys Diagnostic Systems GmbH (Germany), Dialab GmbH (Vienna), Diazyme Laboratories, Inc (US), Wako Pure Chemical Industries, Ltd. (Japan), Ortho Clinical Diagnostics (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
